Ajanta Pharma trades firm in a subdued market as board mulls share buyback
In the past six months, Ajanta Pharma has underperformed the market by gaining 8.9 per cent against 26 per cent rally in S&P BSE Healthcare index
 "Ajanta Pharma trades firm in a subdued market as board mulls share buyback")
premium
Shares of Ajanta Pharma rose 4 per cent to Rs 1,646 on the BSE on Thursday in an otherwise subdued market after the company announced share buyback plan. Intra-day, the stock had rallied 6 per cent to Rs 1,683 in early morning trade. In comparison, the S&P BSE Sensex was down 0.24 per cent at 39,826 points, at 11:27 am.
Earlier, on October 23, 2020, Ajanta Pharma had informed that the board meeting of the Company scheduled to be held on November 03, 2020 to consider, the unaudited consolidated financial results for the quarter and half year ended September 30, 2020 and interim dividend.
“The company has now informed BSE that at the aforesaid board meeting, the board of directors will also consider a proposal for buy-back of the equity shares of the company,” Ajanta Pharma said in regulatory filing on Wednesday after market hours.
As on September 2020, the promoters held 70.51 per cent stake in Ajanta Pharma. Institutional investors led by mutual funds (9.93 per cent) and foreign portfolio investors (7.71 per cent) have collectively held 19.15 per cent, while individual shareholders have 8.57 per cent holding in the company, the shareholding pattern data shows.
In the past six months, the stock has underperformed the market by gaining 8.9 per cent. In comparison, the S&P BSE Healthcare index rallied 26 per cent, while the benchmark the S&P BSE Sensex gained 21.7 per cent during the same period.
Earlier, in March 2019, Ajanta Pharma had bought back 769,230 equity shares of the company at Rs 1,300 per share via tender offer.
In the July-September quarter (Q2FY21), Edelweiss Securities expect Ajanta Pharma’s revenue to grow 5 per cent year-on-year (YoY), led by the US. India will likely remain subdued at 5 per cent decline. The brokerage firm expect EBITDA margin to increase 190bps YoY to 29.5 per cent with some cost savings continuing in Q2.
Earlier, on October 23, 2020, Ajanta Pharma had informed that the board meeting of the Company scheduled to be held on November 03, 2020 to consider, the unaudited consolidated financial results for the quarter and half year ended September 30, 2020 and interim dividend.
“The company has now informed BSE that at the aforesaid board meeting, the board of directors will also consider a proposal for buy-back of the equity shares of the company,” Ajanta Pharma said in regulatory filing on Wednesday after market hours.
As on September 2020, the promoters held 70.51 per cent stake in Ajanta Pharma. Institutional investors led by mutual funds (9.93 per cent) and foreign portfolio investors (7.71 per cent) have collectively held 19.15 per cent, while individual shareholders have 8.57 per cent holding in the company, the shareholding pattern data shows.
In the past six months, the stock has underperformed the market by gaining 8.9 per cent. In comparison, the S&P BSE Healthcare index rallied 26 per cent, while the benchmark the S&P BSE Sensex gained 21.7 per cent during the same period.
Earlier, in March 2019, Ajanta Pharma had bought back 769,230 equity shares of the company at Rs 1,300 per share via tender offer.
In the July-September quarter (Q2FY21), Edelweiss Securities expect Ajanta Pharma’s revenue to grow 5 per cent year-on-year (YoY), led by the US. India will likely remain subdued at 5 per cent decline. The brokerage firm expect EBITDA margin to increase 190bps YoY to 29.5 per cent with some cost savings continuing in Q2.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%